FM
fazen.markets
healthcare·esfritzh

Vycor Medical Revenue Falls 19% as VBAS Sales Normalize

2h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

vycor-medicalvyco-stockvbas-brain-access-systemotcqb-medical-devicesnovavision
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1The company attributed the decline to an unusually strong 2025 comparison rather than to lost accounts.
  • 2The nine-month picture is milder than the quarter.
  • 3Vycor sits in the minimally invasive neurosurgery niche alongside tubular retractor systems sold by larger medtech groups, but the report names no competitor, so no direct peer comparison is available here.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Vycor Medical, Inc. (OTCQB: VYCO) reported third-quarter 2026 revenue of $414,895 on November 13, 2026, a 19% decline from the $513,792 booked in the same quarter of 2025. The Boca Raton-based device maker said its Vycor Medical division, which sells the ViewSite Brain Access System (VBAS), generated $402,048 of that total, down $90,054 or 18% year over year. Gross profit fell 22% to $353,017, and GAAP operating profit narrowed to $27,424 from $32,085.

Context — Why the Revenue Drop Matters Now

The company attributed the decline to an unusually strong 2025 comparison rather than to lost accounts. Vycor said it booked higher-than-normal US sales in the 2025 period from new hospitals and bulk orders placed by some existing hospitals, and that this largely accounts for the shortfall. International sales rose over the three-month window but slipped slightly across the nine-month window, which the company described as normal for a business where large orders can land in different quarters.

The comparison base matters because Vycor's VBAS franchise is a single-product line sold into a slow-moving hospital capital and consumables budget. A bulk order from one health system can swing a quarter by double digits, so the 18% division decline says more about order timing than about underlying demand. The company also flagged that its NovaVision division, still described as a business in development, grew revenue 41% year over year to $12,847 in the quarter.

Management has framed the quarter around clinical validation rather than volume. Vycor said four new peer-reviewed studies on VBAS were published during 2026 to date, bringing total published peer-reviewed clinical papers to 54, with an additional 14 other clinical papers. The company highlighted one paper that called integrating neuro-navigation systems with VBAS a paramount strategy for resecting a complex pediatric tumor.

A second study compared outcomes across 23 patients undergoing tumor resection using VBAS against traditional blade retractors, and the company said it found significantly fewer new neurological deficits at follow-up in the tubular retractor group. A third covered 29 consecutive adults undergoing minimally invasive suboccipital tubular resection of previously untreated posterior fossa metastases. The most recent documented two intracerebral hemorrhage evacuation cases in Japan using VBAS with an exoscope.

There is no macro data point in the release, and the company gave no guidance, no backlog figure and no order book disclosure. That silence is itself relevant: investors cannot separate the one-time bulk-order effect from any change in the run rate without those numbers.

Data — What the Numbers Show

The nine-month picture is milder than the quarter. Vycor reported nine-month revenue of $1,291,699, an 11% decline from $1,446,523. The Vycor Medical division produced $1,243,713, down $148,697 or 11%, while NovaVision contributed $47,986, up 11%. Gross profit for the nine months was $1,072,615, a 12% decrease, with margin easing to 83% from 85%.

MetricQ3 2026Q3 20259M 20269M 2025
Revenue$414,895$513,792$1,291,699$1,446,523
Vycor Medical revenue$402,048$492,102$1,243,713$1,392,410
NovaVision revenue$12,847$21,690$47,986$54,113
Gross margin85%88%83%85%
GAAP operating profit$27,424$32,085$80,083$70,425
Non-GAAP operating profit$43,011$60,162$125,751$166,262

Cost of goods sold was nearly flat at $61,878 against $61,860, so the margin compression came from revenue mix rather than from input costs. Non-GAAP cash operating expenses fell to $310,006 from $391,770 in the quarter, and to $946,864 from $1,059,475 over nine months. The nine-month GAAP operating profit actually improved to $80,083 from $70,425, because the 2025 period carried $48,838 of stock-based compensation and $9,963 of research and development expense that did not repeat.

Net loss available to common stockholders was $161,447, or $0.00 per share, in the quarter, against $157,249 a year earlier. The nine-month net loss narrowed to $325,812 from $334,110. Preferred stock dividends of $162,185 per quarter, unchanged year over year, are what push a small operating profit into a loss attributable to common holders. Weighted average shares outstanding were 33,372,796 in both periods.

Analysis — What It Means for the Sector

Vycor sits in the minimally invasive neurosurgery niche alongside tubular retractor systems sold by larger medtech groups, but the report names no competitor, so no direct peer comparison is available here. What the numbers do show is a company whose operating expenses have fallen faster than revenue: non-GAAP cash operating expenses dropped 21% in the quarter against a 19% revenue decline, which is why the nine-month GAAP operating line improved despite lower sales.

The counter-argument is that cost discipline on a $1.3 billion-adjacent revenue base is not a growth story. A device company with roughly $1.29 billion in nine-month revenue — actually $1.29 million — depends on hospital adoption, and the company's own explanation for the shortfall is that 2025 pulled forward demand from new accounts and bulk buyers. If those orders were genuinely one-time, the 2026 base is the cleaner run rate; if they represented accounts that have since lapsed, the decline is structural. The report does not let a reader distinguish between the two.

NovaVision is the smaller swing factor. The company said its Visual Restoration Therapy is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, and that NeuroEyeCoach is supported by a 296-patient study with improvement in over 80% of patients. It also said plainly that the therapies still require significant development to address their market potential. That is a candid admission that the division is not yet a revenue driver at $47,986 over nine months.

Positioning here is thin. VYCO trades on the OTCQB venture tier, where flow is dominated by retail and small institutional holders rather than by index or quant funds. The stock's reaction to this release will hinge on whether readers treat the 19% decline as timing noise or as the start of a trend.

Outlook — What to Watch Next

The report gives no earnings date, no guidance and no target. The next hard data point will be the company's full-year 2026 results, which the release does not schedule. Between now and then, watch the fourth-quarter Vycor Medical division revenue for evidence on whether the bulk-order effect has fully lapped, and watch NovaVision for whether the 41% quarterly growth rate holds on a small base.

The company's patent position is a longer-dated factor: VBAS is protected by 49 issued and 8 pending patents, and the company said the system has been approved and used in over 350 US hospitals and in numerous countries internationally. Any disclosure of new hospital additions or international order concentration would be the clearest signal on whether the 2026 decline reverses. The report does not disclose the terms of any financing, and no capital raise was mentioned.

Frequently Asked Questions

Why did Vycor Medical's revenue fall in the third quarter of 2026?

The company said the decline was mostly a comparison effect. Its 2025 period included higher-than-normal US sales from new hospitals and bulk orders placed by some existing hospitals. International sales rose over the three months but fell slightly over nine months, which the company said is typical when large orders fall in different quarters. Cost of goods sold was essentially flat, so the drop came from volume, not pricing.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related